Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

By afschroeder • November 6, 2026

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller GJ, Abedi M, Minnema MC, Stiff P, Zhou L, Adhikary S, Khalid RD, Shah BD. Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2026 Nov 5:S2666-6367(26)00872-9. doi: 10.1016/j.jtct.2026.11.003. Epub ahead of print. PMID: 42988007.

Tags: acute, adult, B cell, Brexucabtagene autoleucel, CAR T-cell therapy, Hematology/Oncology, leukemia, long-term survival, Lymphoblastic Leukemia, Lymphocytic, Publications, ZUMA-3

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]

Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

Valentín López JC, Ho A, Hughes KS, Bardia A, Vidula N. Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from[...]